03.07.2023 • NewsNovartisdivestTakeda

Novartis Divests Ophthalmology Assets to Bausch + Lomb for Up to $2.5 Billion

Novartis has signed an agreement to divest its 'front of eye' ophthalmology assets to Bausch + Lomb, a global eye health company. The transaction is valued at up to $2.5 billion, which marks a strategic move to focus on innovative medicines and growth opportunities.

The deal includes assets such as Xiidra, the first approved treatment for dry eye disease, libvatrep, an in-development medication for chronic ocular surface pain, and other promising therapies for ocular conditions.  

This move enables Novartis to prioritize its growth strategy and concentrate on other innovative medicines with a substantial impact on patients. Previously Takeda had sold Xiidra to Novartis in 2019 for $3.4 billion upfront plus additional milestone payments.  

“We believe that Bausch + Lomb has the capabilities, scale, and commitment to continue the work of Novartis in delivering and developing much-needed therapies for patients suffering from dry eye and related conditions”, says Ronny Gal, Chief Strategy & Growth Officer of Novartis. 

The agreement dictates that Novartis will receive milestone payments of up to $750 million linked to the future sales of the pharmaceuticals. Novartis will continue to supply Xiidra for a limited time until Bausch + Lomb takes over, ensuring patients receive a consistent supply. Closing is expected by the end of 2023.  

Novartis Pavillon. Novartis divests ophthalmology assets to  Bausch + Lomb. ©...
Novartis Pavillon. Novartis divests ophthalmology assets to Bausch + Lomb. © Novartis AG

Free Virtual Event

Digital Validation
Transforming from Paper to Digital

Digital Validation

Our experts will delve into the recently released International Society for Pharmaceutical Engineering (ISPE) Good Practice Guide: Digital Validation

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.